Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» ASCO: Lilly's abemaciclib vs. Pfizer's Ibrance? Too early to make a call, analysts say
ASCO: Lilly's abemaciclib vs. Pfizer's Ibrance? Too early to make a call, analysts say
ASCO: Lilly's abemaciclib vs. Pfizer's Ibrance? Too early to make a call, analysts say
Submitted by
admin
on May 18, 2017 - 8:00pm
Source:
Fierce Pharma
News Tags:
ASCO 2017
Eli Lilly
Pfizer
abemaciclib
Ibrance
breast cancer
Headline:
ASCO: Lilly's abemaciclib vs. Pfizer's Ibrance? Too early to make a call, analysts say
Do Not Allow Advertisers to Use My Personal information
